Nanobiotix S.a. cash flow statement

In fiscal 2025, Nanobiotix S.a.'s operations generated −$37.8m of cash; it spent $608,274 on capital projects, leaving free cash flow of −$38.4m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Nanobiotix S.a.: cash flow statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−31	−46	−31	−35	−39	−13	−21	−38
Depreciation and amortisation	1	2	2	2	2	2	2	2
Stock-based pay	2	5	3	4	3	3	5	4
Capital spending	0	1	0	0	0	0	1	1
Free cash flow	−31	−47	−32	−36	−39	−14	−22	−38
Free cash flow after stock pay	−33	−52	−35	−39	−43	−17	−27	−42

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: FHTX vs NBTX NBTX vs ZYME CUE vs NBTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nanobiotix S.a.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nanobiotix S.a.